Australia markets open in 7 hours 31 minutes

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
19.54-0.34 (-1.71%)
As of 12:28PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close19.88
Bid19.43 x 100
Ask19.61 x 100
Day's range19.21 - 19.74
52-week range12.32 - 32.10
Avg. volume796,522
Market cap937.455M
Beta (5Y monthly)-0.49
PE ratio (TTM)N/A
EPS (TTM)-2.17
Earnings date01 Aug 2024 - 05 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Dec 2012
1y target est103.00
  • Zacks

    Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross

    When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

  • GlobeNewswire

    Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

    $126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 mill

  • GlobeNewswire

    Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

    Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per ShareAUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distributed to its shareholders (the “Warrants”). Gross proceeds from the Warrants represents the issuance of